Softwr

Healthcare · head to head

Gleamer vs Woebot Health

Gleamer logo

Gleamer

Healthcare

CE marked and FDA cleared imaging AI suite for bone trauma and chest, now owned by RadNet

From
On request
Rated
-
Full reviewWebsite
Woebot Health logo

Woebot Health

Healthcare

Conversational CBT chatbot that withdrew from consumer distribution and now sells only to payers and providers

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Gleamer radNet, an imaging provider that competes with many independent Gleamer customers, now owns the company and also owns the competing DeepHealth AI portfolio, so roadmap and pricing priorities are an open question for non-RadNet buyers.; Woebot Health the company withdrew its consumer app in June 2025 after concluding FDA marketing authorisation was not achievable at acceptable cost, which is a plain signal about both regulatory position and commercial durability.
  • They diverge on capability: Gleamer covers BoneView, Woebot Health covers Scripted CBT dialogue.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Gleamer and Woebot Health actually diverge.

Attributes where Gleamer and Woebot Health differ
AttributeGleamerWoebot Health
PlatformsWeb, Cloud, On-premiseiOS, Android, Web

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Gleamer

  • BoneView
  • ChestView
  • BoneAge
  • BoneMetrics
  • LungCT and BoneCT
  • BreastView
  • Pixyl.Neuro
  • Gleamer Copilot

Only in Woebot Health

  • Scripted CBT dialogue
  • Mood tracking
  • Crisis routing
  • Between-session support
  • Payer deployment
  • Provider copilot positioning
  • Research licensing
  • Population reporting

What people use each for

The jobs each tool is most often brought in to do.

Gleamer

  • An emergency department where junior doctors read plain films before radiology review and missed fractures are a recurring incident themenot Woebot Health
  • An urgent care network standardising musculoskeletal reading quality across sites with variable radiology covernot Woebot Health
  • A paediatric service automating bone age assessment to remove a slow manual atlas comparisonnot Woebot Health
  • An orthopaedic service that needs automated limb alignment and measurement before surgical planning rather than manual measurement on the workstationnot Woebot Health

Woebot Health

  • A health plan wanting a low intensity behavioural health option for members on a waiting list for therapynot Gleamer
  • A provider organisation offering structured between-session CBT practice to patients already in treatmentnot Gleamer
  • A research group running a trial that needs a clinically scripted rather than generative conversational agent for safety reasonsnot Gleamer
  • A payer targeting a specific population such as postpartum members where scripted CBT content already existsnot Gleamer

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Gleamer

  • RadNet, an imaging provider that competes with many independent Gleamer customers, now owns the company and also owns the competing DeepHealth AI portfolio, so roadmap and pricing priorities are an open question for non-RadNet buyers.
  • The measured benefit is largest for less experienced readers, so a specialist musculoskeletal service will see far less improvement than the published reader studies suggest.
  • Cleared indications differ per module and per market, and the FDA cleared set is narrower than the CE marked European set, so an American buyer cannot rely on European reference sites.
  • Each additional module adds alert volume into the same worklist, and departments running several Gleamer algorithms report needing local threshold tuning to keep radiologist trust.
  • Pricing is per exam and not published, which makes budgeting difficult for an emergency department whose plain film volume swings seasonally.

Woebot Health

  • The company withdrew its consumer app in June 2025 after concluding FDA marketing authorisation was not achievable at acceptable cost, which is a plain signal about both regulatory position and commercial durability.
  • It is not an FDA cleared treatment for any indication, so it cannot be positioned to members as therapy and cannot substitute for a covered behavioural health benefit.
  • The scripted, non-generative design that makes it safe also makes it feel rigid next to current conversational AI, and engagement drops off quickly once users hit the edges of the script.
  • Published evidence is short-horizon symptom change in selected populations, mostly young adults, with little evidence of durable benefit or effect at whole-population scale.
  • With consumer distribution gone, the remaining business depends on a small number of payer and provider contracts, so a buyer should assume real vendor continuity risk over a multi-year term.

Pricing, plan by plan

Gleamer

On request
  • Gleamer Copilot$undefined/year
    • Priced per exam analysed or as an annual volume subscription
    • Modules licensed individually or bundled as Copilot
    • Cleared and CE marked indication differs per module and per market

Woebot Health

On request
  • Woebot for payers and providers$undefined/year
    • Contracted per member per month or as a population licence
    • Sold to health plans and provider organisations, not to employers or individuals
    • No consumer purchase route since the app closed in June 2025

Which should you pick?

Choose Gleamer if

  • You need boneview.
  • You work on Web, Cloud, On-premise.
  • You also want chestview.
Gleamer review

Choose Woebot Health if

  • You need scripted cbt dialogue.
  • You work on iOS, Android, Web.
  • You also want mood tracking.
Woebot Health review

Questions people ask

Is Gleamer or Woebot Health better?
Neither clearly leads. Gleamer starts at On request and Woebot Health at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Gleamer or Woebot Health?
Gleamer starts at On request and Woebot Health at On request.
Does Gleamer or Woebot Health run on more platforms?
Gleamer runs on Web, Cloud, On-premise. Woebot Health runs on iOS, Android, Web.
What is Gleamer best used for?
Gleamer is most often used for an emergency department where junior doctors read plain films before radiology review and missed fractures are a recurring incident theme, an urgent care network standardising musculoskeletal reading quality across sites with variable radiology cover, a paediatric service automating bone age assessment to remove a slow manual atlas comparison, an orthopaedic service that needs automated limb alignment and measurement before surgical planning rather than manual measurement on the workstation. Of those, an emergency department where junior doctors read plain films before radiology review and missed fractures are a recurring incident theme and an urgent care network standardising musculoskeletal reading quality across sites with variable radiology cover are not what Woebot Health is typically brought in for.
What can Gleamer do that Woebot Health cannot?
Gleamer covers BoneView, ChestView, BoneAge, BoneMetrics. Woebot Health covers Scripted CBT dialogue, Mood tracking, Crisis routing, Between-session support.

Answered from the vendors’ own pages

Gleamer: Who owns Gleamer?

RadNet agreed to acquire Gleamer in February 2026 for around two hundred and fifteen million euros upfront. RadNet also owns DeepHealth, a competing AI portfolio.

Woebot Health: Is Woebot still available?

Not to consumers. The consumer app closed in June 2025. The company continues to offer the product to payers, providers and researchers.

Gleamer: Is BoneView FDA cleared?

Yes, BoneView holds 510(k) clearance including for paediatric fracture detection, but the cleared finding set is narrower than the CE marked indication in Europe.

Woebot Health: Is it FDA cleared?

No. It held Breakthrough Device designation but never obtained marketing authorisation, and the founder cited the cost of that pathway as the reason for closing the consumer app.

Gleamer: What does the evidence actually show?

Multi-reader studies reported improved reader sensitivity for fracture detection and fewer false negatives, with the gain concentrated among less experienced readers in emergency settings.

Woebot Health: Is it generative AI?

Historically no. The dialogue is clinician-written and rule-based, a deliberate safety choice that limits how naturally it converses.

Gleamer: Can I buy just BoneView?

Yes, modules are licensed individually, though the commercial pitch is now the Copilot bundle across modalities.

Woebot Health: What does the evidence show?

Randomised studies reported reduced depressive symptoms over short periods in selected populations, notably young adults. That is symptom change in a trial, not demonstrated population outcomes.

Share

Related pages

More on Gleamer

More on Woebot Health

Keep looking

Other head to heads